Safest Choice of Antihypertensive Regimen for Postpartum Hypertension

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 500 participants.

Also called NCT05551104

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 500 participants (planned count) (from the registry)
Sponsor
Loma Linda University (from the registry)
Registry
  • NCT NCT05551104
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05551104. Randomized; no masking; primary purpose treatment. Start 2023-05-08 (actual); primary completion 2027-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safest Choice of Antihypertensive Regimen for Postpartum Hypertension
Acronym
SCARPH
Condition
Postpartum Complication
Condition
Maternal Hypertension
Intervention (Drug)
Oral Nifedipine
Intervention (Drug)
Oral Labetalol
Lead sponsor
Loma Linda University (class: other)

Record details

Record id
cardio:ct-nct05551104
Content hash
752efe1dad4515ea4547ea9a6686d58ff306871bdba349fa5b14d39aab566f0f